Skip to content

The Low Cost of Universal Access

  • Chad Cipiti

Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability By Tracy Swan TAG talks with Andrew Hill, senior visiting research fellow in the University of Liverpool’s Department of Pharmacology, about his group’s work…

Read more

PrEP Pricing Problems

  • Chad Cipiti

A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them By James Krellenstein and Jeremiah Johnson On July 16, 2012, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences’…

Read more

HIV Community Letter to Hillary for America

  • Chad Cipiti

Dear Secretary Clinton: We write to you in the sincere hope that we can work together to transform the pain caused by your March 11th mischaracterization of the Reagans’ role in the AIDS crisis into an urgently needed public discussion of a plan to end the United States HIV epidemic by the year 2025.

Read more

Pre-CROI Community HIV Cure Research Workshop 2016

  • Chad Cipiti

On Sunday February 21, 2016 in Boston, the AIDS Treatment Activists Coalition, AVAC, European AIDS Treatment Group, Project Inform and TAG co-sponsored a community workshop on HIV cure research. The workshop has become an annual event that takes place immediately…

Read more

Envisioning Comprehensive HIV Prevention Service Delivery in the U.S.

  • Chad Cipiti

RELATED: Toward Comprehensive HIV Prevention Service Delivery in the United States: An Action Plan December 18, 2015 A collaboration between Treatment Action Group and the HIV Prevention Justice Alliance, this webinar discusses the current state of the HIV prevention toolbox…

Read more

2015 TAG Update

  • Chad Cipiti

TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.

Read more
Back To Top